Clinical Trials Related to Metastatic Hormone-sensitive Prostate Cancer

Related studies linked through entity extraction aliases.

A Study to Assess Adherence to Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer Participants in France

Status: RECRUITING
Phase: N/A

PSMA PET/CT-Based Multimodal Model for Predicting Response to First-Line Therapy in mHSPC.

Status: COMPLETED
Phase: N/A

A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics

Status: RECRUITING
Phase: N/A

A Study to Learn How Men With Advanced Prostate Cancer Respond to Treatment With Darolutamide and Hormone Therapy, With or Without Chemotherapy, in Real-world Medical Practice

Status: ACTIVE_NOT_RECRUITING
Phase: N/A

Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial.

Status: NOT_YET_RECRUITING
Phase: PHASE3

Evaluation of the Efficacy of Darolutamide Triplet Therapy in Patients With Metastatic Hormone-sensitive Prostate Cancer

Status: NOT_YET_RECRUITING
Phase: N/A

An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Status: RECRUITING
Phase: PHASE2

An Observational Study to Learn More About Treatment Patterns and Factors Determining the Choice of Treatment in Canadian Men With Metastatic Hormone Sensitive Prostate Cancer in Routine Medical Care

Status: ACTIVE_NOT_RECRUITING
Phase: N/A

An Observational Study to Learn More About the Use of Darolutamide as a Part of a Combination Therapy in Belgian Men With Metastatic Hormone-Sensitive Prostate Cancer in Routine Medical Care

Status: COMPLETED
Phase: N/A

Non-Interventional Study to Establish Consensus on Management of Metastatic Hormone-Sensitive Prostate Cancer Patients

Status: COMPLETED
Phase: N/A

An Observational Study to Learn More About the Safety of Darolutamide in Men With Prostate Cancer in Korea

Status: RECRUITING
Phase: N/A

Rezvilutamide Plus Abiraterone for Metastatic Hormone-sensitive Prostate Cancer

Status: NOT_YET_RECRUITING
Phase: PHASE2

A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or Enzalutamide

Status: ACTIVE_NOT_RECRUITING
Phase: N/A

A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer

Status: RECRUITING
Phase: PHASE1

Survey Based Discrete Choice Experiment Study in Prostate Cancer (DECIDER) Study

Status: COMPLETED
Phase: N/A

A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study.

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension

Status: COMPLETED
Phase: PHASE3

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)

Status: COMPLETED
Phase: PHASE3

A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer

Status: UNKNOWN
Phase: PHASE2/PHASE3

Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer

Status: COMPLETED
Phase: PHASE1